cardiac myosin — Drug Target

All drugs that target cardiac myosin — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Cardiac Myosin Inhibitor [EPC] · Cardiac myosin activator · Cardiac myosin inhibitor · cardiac myosin inhibitor

Marketed (1)

• Camzyos · Bristol-Myers Squibb · Cardiac Myosin Inhibitor [EPC] · Cardiovascular
  Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM.

Phase 3 pipeline (2)

• Omecamtiv Mecarbil (OM) · Cytokinetics · Cardiac myosin activator · Cardiovascular
  Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole.
• TNX-103 · Tenax Therapeutics, Inc. · Cardiac myosin inhibitor · Cardiovascular
  TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients.

Phase 2 pipeline (1)

• CK-2017357 · Cytokinetics · cardiac myosin inhibitor · Cardiovascular
  CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.